跳至主要内容
临床试验/DRKS00011390
DRKS00011390进行中(未招募)未知

The influence of immunotherapy and chemotherapy accompanying endurance training on incidence and severity of cognitive deficits as well as other therapy-induced side effects and complications in oncological patients. A randomized controlled trial - CIM

niversitäres Centrum für Tumorerkrankungen (UCT) FrankfurtKrankenhaus NordwestKlinik für Onkologie und Hämatologie0 个研究点目标入组 2 人开始时间: 2018年1月17日最近更新:
适应症

试验速览

阶段
未知
状态
进行中(未招募)
发起方
入组人数
2

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 70 Years(—)
性别
All

入选标准

  • Entities: Bronchial Carcinoma (NSCLC), Bladder Carcinoma, Malignant Melanoma, Renal Cell Carcinoma, Gastrointestinal Tumors, Triple-negative Mamma CA
  • PD-1, PD-L1, CTLA4 Receptor +
  • Upcoming first or second-line therapy (t0 before therapy)

排除标准

  • Comorbidities that prevent participation in exercise intervention (e.g. CHD, Heart failure NYHA>3, orthopedic disorders, cerebral spasms, psychological diseases that do not allow intervention from the point of view of the study physician)
  • Upcoming, planned surgery in intervention period
  • Formation of metastases in the central nervous system or osseous with danger of stability
  • A medical or mental condition which, in the opinion of the investigator, does not permit the patient to participate in the study or to provide a legally valid signature on the informed consent form.
  • Presence of cognitive impairments of other causes (e.g. dementia, multiple sclerosis, condition after apoplexy/skull-brain trauma, condition after brain tumor) unwillingness to store and share personal medical data under the Protocol

研究者

发起方
niversitäres Centrum für Tumorerkrankungen (UCT) FrankfurtKrankenhaus NordwestKlinik für Onkologie und Hämatologie

相似试验